Investigating how small molecules can lower prion protein levels in the brain
Official title: Mechanism of Action of Prion Protein-Lowering Small Molecules
Funded at Broad Institute, INC. · NIH-11056891 · Data updated 2026-11-12
This study is looking at new small molecules that might help lower harmful protein levels in the brains of people with prion diseases, with the hope of finding better treatments for these serious conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Broad Institute, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $378,000 |
| NIH project number | 5R01NS131663-03 |
| Project ID | NIH-11056891 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with prion diseases or those at risk of developing such conditions.
✕Less likely to help
Patients with prion diseases who are already in advanced stages of the illness may not benefit from this research.
What this research studies
This research focuses on prion diseases, which are severe neurodegenerative conditions caused by abnormal forms of a protein called prion protein (PrP). The study aims to explore the mechanisms by which newly identified small molecules can reduce PrP levels in the brain, potentially offering a new therapeutic approach. By utilizing advanced molecular biology techniques, the researchers will investigate how these compounds work and their effects in living organisms. This could lead to a better understanding of prion biology and the development of effective treatments.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce the progression of prion diseases, improving outcomes for affected patients.
How similar studies have gone: While the approach of using small molecules to lower PrP levels is innovative, similar strategies have shown promise in other neurodegenerative conditions, indicating potential for success.
Where this research is happening
-
Broad Institute, INC.
Cambridge, United States Active
Researchers
- Principal investigator: Vallabh, Sonia Minikel — Broad Institute, INC.
- Study coordinator: Vallabh, Sonia Minikel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.